Article Text

Download PDFPDF

LP-176 SARS-CoV-2 antibody formation after COVID-19 vaccination in SLE patients treated with belimumab: single-center prospective observational study
  1. Eunsong Kang1,
  2. Soo Min Ahn1,
  3. Seokchan Hong1,
  4. Ji Seon Oh1,2,
  5. Chang Keun Lee1,
  6. Bin Yoo1 and
  7. Yong Gil Kim1
  1. 1Division of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
  2. 2Department of Information Medicine, Big Data Research Center, Asan Medical Center, Seoul, Republic of Korea


Background Patients with systemic lupus erythematosus (SLE) should be more proactive with the administration of the COVID-19 vaccine, as their systemic conditions are prone to developing severe outcomes. However, there are concerns that immunosuppressive agents used in SLE patients could reduce the immune response. Previous data demonstrates that total B-cell depletion impairs the humoral response in patients treated with Rituximab, but there is very limited information about Belimumab. Thus, we aimed to assess the immunogenicity and safety of COVID-19 vaccine in SLE patients treated with Belimumab.

Methods Patients with SLE receiving B-cell targeted therapy with Belimumab were recruited from December 14, 2021, to June 17, 2022. We reviewed the patients’ immunization history and measured the antibody titers of patients who had completed their third dose of COVID-19 vaccine. SARS-CoV-2 antibody titers were determined through semiquantitative anti-SARS-CoV-2 S enzyme immunoassay.

Results A total of 21 patients with SLE receiving Belimumab treatment were surveyed, out of which 10 patients had completed 3 doses of COVID-19 vaccinations. The mean duration between the last (3rd) vaccination date and the date of sample acquisition was 22.5 weeks, and there was no patient with side effects other than mild myalgia. The antibody titers were positive in all 10 patients, with 8 patients showing high antibody titers of 250 U/mL or more. The other 2 patients measured relatively low antibody titers of 117 U/mL and 112 U/mL, with a treatment history with Rituximab within one year and current treatment with hydroxychloroquine, respectively.

Conclusions Our findings suggest that Belimumab does not compromise the antibody production from the vaccination. SLE patients with Belimumab need not be reluctant to get COVID-19 vaccines in regard to humoral response impairment.

  • systemic lupus erythematosus
  • Belimumab
  • SARS-CoV-2 Antibody Formation

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.